Molecular Assemblies

Executive Summary

Molecular Assemblies, now integrated into TriLink BioTechnologies, has pioneered a fully enzymatic DNA synthesis (FES™) platform capable of producing oligonucleotides up to 400 bases in length with ultra-high purity, eliminating the need for costly post-synthesis purification steps such as PAGE or HPLC. This breakthrough accelerates research and development across critical fields including oncology, immunology, infectious diseases, agriculture, and nanotechnology by providing fast turnaround, accurate, and scalable DNA synthesis. The acquisition by TriLink BioTechnologies, a leader in nucleic acid manufacturing, validates the commercial potential of the FES platform and positions it for broader market adoption. Looking ahead, Molecular Assemblies is poised to capitalize on the growing demand for long, high-quality oligonucleotides in emerging therapeutic modalities such as mRNA therapeutics, gene editing, and personalized medicine. The company's technology addresses key bottlenecks in DNA synthesis, offering a cost-effective and environmentally friendly alternative to traditional chemical methods. With TriLink's extensive distribution network and manufacturing capabilities, Molecular Assemblies is well-equipped to scale its platform and capture significant market share in the rapidly expanding synthetic biology and nucleic acid therapeutics markets.

Upcoming Catalysts (preview)

• Q4 2026Extension of enzymatic synthesis capability to over 500 bases60% success
• Q3 2026Announcement of a major partnership with a top pharmaceutical company for therapeutic oligonucleotide supply45% success
• Q1 2027Expansion of FES platform into GMP-grade manufacturing for clinical applications50% success